Treatment trials in young patients with chronic obstructive pulmonary disease and pre–chronic obstructive pulmonary disease patients: time to move forward

FJ Martinez, A Agusti, BR Celli, MLK Han… - American journal of …, 2022 - atsjournals.org
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and
cumulative gene–environment interactions over a lifetime. The evolving understanding of …

Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people

O Ivanova, VS Hoffmann, C Lange… - European …, 2023 - Eur Respiratory Soc
Background A substantial proportion of tuberculosis patients remain with pulmonary
symptoms and reduced physical capacity despite successful treatment. We performed a …

Contribution of adaptive immunity to human COPD and experimental models of emphysema

F Kheradmand, Y Zhang, DB Corry - Physiological Reviews, 2023 - journals.physiology.org
The pathophysiology of chronic obstructive pulmonary disease (COPD) and the undisputed
role of innate immune cells in this condition have dominated the field in the basic research …

[HTML][HTML] Impact of the metabolic syndrome on cardiopulmonary morbidity and mortality in individuals with lung function impairment: a prospective cohort study of the …

JL Marott, TS Ingebrigtsen, Y Çolak… - The Lancet Regional …, 2023 - thelancet.com
Background Whether the metabolic syndrome plays a role for the prognosis of individuals
with lung function impairment (preserved ratio impaired spirometry (PRISm) or airflow …

[HTML][HTML] Cardiovascular predictors of mortality and exacerbations in patients with COPD

P Alter, T Lucke, H Watz, S Andreas, K Kahnert… - Scientific Reports, 2022 - nature.com
In chronic obstructive pulmonary disease (COPD), comorbidities and worse functional status
predict worse outcomes, but how these predictors compare with regard to different outcomes …

Clinical relevance of lung function trajectory clusters in middle-aged and older adults

X Bertels, JC Ross, R Faner, MH Cho… - ERJ Open …, 2024 - Eur Respiratory Soc
Background The determinants and health outcomes of lung function trajectories in adults
among the general population are poorly understood. We aimed to identify and characterise …

[HTML][HTML] Improved exercise capacity results in a survival benefit after endobronchial valve treatment

SA Roodenburg, DJ Slebos, M van Dijk, TD Koster… - Respiratory …, 2023 - Elsevier
Background Bronchoscopic lung volume reduction using endobronchial valves (EBV) is a
treatment option for selected patients with advanced emphysema. The treatment significantly …

Fibrinogen, a promising marker to evaluate severity and prognosis of acute exacerbation of chronic obstructive pulmonary disease: a retrospective observational study

W Sun, Z Cao, Y Ma, J Wang, L Zhang… - International Journal of …, 2022 - Taylor & Francis
Background Fibrinogen is increasingly being studied as an inflammatory biomarker in
chronic obstructive pulmonary disease (COPD), but there are limited data on the role of …

Genetically Predicted Body Mass Index and Mortality in COPD

J Zhang, M Moll, BD Hobbs, P Bakke… - American Journal of …, 2024 - atsjournals.org
Rationale: BMI is associated with COPD mortality, but the underlying mechanisms are
unclear. The effect of genetic variants aggregated into a polygenic score may elucidate …

[HTML][HTML] Quality of life and mortality outcomes for augmentation naïve and augmented patients with severe alpha-1 antitrypsin deficiency

PR Ellis, KE Holm, R Choate, DM Mannino… - … Diseases: Journal of …, 2023 - ncbi.nlm.nih.gov
Background: Intravenous alpha-1 antitrypsin (AAT) augmentation therapy is the only specific
treatment available for alpha-1 antitrypsin deficiency (AATD)-related lung disease. It is …